EXHIBIT A

UNITED STATES DISTRICT COURT DISTRICT OF MASS/

MDL Docket No. 1629 Master File No. 04-1(

In re: NEURONTIN MARKETING,

SALES PRACTICES AND PRODUCTSLIABILITY LITIGATION

_____xTHIS DOCUMENT RELATES TO:

Bulger v. Pfizer, et al.

07-CV-11426-PBS_____x

VIDEO DEPOSITION OF JANET ARROWSMITH-LOWE, M.D. Jar

9:18 a.m. Homewood Suites by Hilton

7101 Arvada Avenue, N.E. Albuquerque, New Mexic

PURSUANT TO THE FEDERAL RULES OF CIVILPROCEDURE, this depositior

TAKEN BY: MR. KEITH L. ALTMAN

Attorney for the Products Liability Plaintiffs

REPORTED BY: Jan A. Williams, RPR, CCR 14 Bean & Associates

Professional Court Reporting Service 201 Third

Albuquerque, New Mexico 87102

(1945D) JAW

A. I know about the practices of FDA and what data are available to FDA. And based on that I can estimate that probably they did know about Neurontin's off-label use.

MR. BARNES: Is this a good time to break for lunch?

MR. ALTMAN: Yeah, if you want to. Why don't we go off the record.

THE VIDEOGRAPHER: We are off the record. The time now is 12:21 p.m.

(Recess.)

THE VIDEOGRAPHER: We are on the record. The time now is 1:15 p.m.

BY MR. ALTMAN:

Q. Dr. Arrowsmith-Lowe, we're going to move off of your addendum to your supplemental report and onto some other things.

A. Okay.

Q. Are you aware that in the end of January of 2008, the FDA came out with an alert associated with anticonvulsant drugs and suicidality?

A. Yes, I'm aware of that.

Q. Have you read that alert?

A. Yes.

Q. Okay. Are you aware that in May of 2008, the

FDA published a statistical review associated with that alert?

A. I'm aware of that, yes, of that statistical review, yes.

Q. Did you review that statistical review?

A. Yes, I've read it.

Q. Okay. Are you aware that in July of 2008, the FDA convened an advisory committee to discuss what proposed label changes associated with the anticonvulsants and suicidality?

MR. BARNES: Objection, incomplete question regarding what the advisory committee did. But go ahead and answer.

THE WITNESS: I'm aware that FDA convened a joint advisory committee, yes, to discuss AEDs and suicide.

BY MR. ALTMAN:

Q. Okay. Did you review that transcript?

A. Yes.

Q. At the time the FDA alert came out, were you qualified to render opinions based upon the FDA alert?

A. I don't understand what you're asking me.

Q. Were you qualifying to render opinions concerning the FDA alert and what it means and what it meant for Neurontin?

A. I believe so, yes.
Q. When the statistical analysis came out in May of 2008, were you qualified to render opinions based upon the FDA's statistical review and its adequacy and completeness and appropriateness?
A. Yes.
Q. When the -- when you read the advisory committee transcript in July -- from July of 2008, were you qualified to render opinions based upon what was discussed at the advisory committee?
A. In my opinion, yes.
Q. Okay. Thank you. Dr. Arrowsmith-Lowe, are you familiar with the term a Daubert hearing?
A. I generally know what it means, yeah.
Q. And I think you've been subject to Daubert hearings in the past, correct?
A. I don't know.
Q. Do you know if a court has ever reviewed your expert reports and depositions to decide whether you were -- would be allowed to testify in court?
A. I don't know.
Q. What's your understanding of what a Daubert hearing is?
A. Well, I thought it had to do with the quality or the appropriateness of the data on which a claim is